Deception and Debriefing in Research

Deception is rarely used in clinical research because clinical populations often involve more-than-minimal-risk procedures, and concealing information about medical risks or interventions is generally unethical. However, deception about certain aspects of a clinical trial (e.g., which treatment group a patient is assigned to in a double-blind trial) is standard and is disclosed in informed consent ('you will not know which treatment you receive'). In contrast, deception about the treatment itself (telling a patient they are receiving an experimental drug when they are receiving placebo) would be unethical unless disclosed. When in doubt, consult your ethics committee.

No. Full debriefing is a mandatory protection in deceptive research; withholding information about deception because you fear it might upset participants is paternalistic and violates ethics frameworks. Instead, the ethical solution is to ensure robust debriefing: explain the deception, provide clear rationale, assess understanding, and offer support (referrals to counseling, opportunity to discuss feelings). If you believe debriefing will cause significant harm, the implication is that the deception itself was too risky and the study should not have been approved in the first place. Do not use 'debriefing harm' as justification for incomplete disclosure.

Remain calm and supportive. Continue the debriefing explanation, ensuring the participant understands the deception was ethically reviewed and necessary. Allow time for questions and discussion. Assess the source of distress: Is it surprise/embarrassment about being deceived, or distress about what the study revealed (e.g., they learned they have implicit bias)? Provide perspective and normalization: 'Implicit bias is common in all people and does not reflect your character.' Offer mental health resources if distress is significant or persistent. Document the participant's reaction and any support offered. Report to your IRB/REC if the distress is substantial, as it may indicate the study involved greater-than-anticipated harm.

This is ethically complex. Broadly, yes—respecting participant autonomy means honoring a request not to be debriefed. However, researchers should gently encourage debriefing by explaining its importance ('Understanding how the study worked helps us ensure it was conducted ethically and may answer questions you have'). If a participant adamantly refuses, document this and respect the choice. However, you still must provide written information about the deception and researcher contact information in case the participant wants to discuss it later. Complete silence about deception would violate ethical obligations.